Vaderis's $152M War Chest and Pivotal Trial Signal a New Dawn for HHT

BASEL, Switzerland – August 11, 2026

In the world of biopharmaceutical development, capital and clinical progress are the twin engines of innovation. Today, Vaderis Therapeutics fired up both in a dramatic fashion. The company announced a dual milestone that could fundamentally alter the landscape for a rare and debilitating genetic disorder: the closing of an oversubscribed $152 million Series B financing and the simultaneous initiation of a global Phase 3 clinical trial for its lead drug candidate, engasertib. This one-two punch propels the company into its final development stage, offering the first tangible hope for a dedicated, approved therapy for patients with Hereditary Hemorrhagic Telangiectasia (HHT).

The Smart Money Bets on Rarity

An oversubscribed $152 million funding round is a significant event for any clinical-stage company, but the syndicate behind Vaderis's latest financing tells a deeper story. Co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, the round attracted a who's who of sophisticated healthcare investors, including Omega Funds, EQT Life Sciences, and Perceptive Advisors, alongside steadfast existing backers Medicxi and Droia. This isn't just a bet on a single drug; it's a calculated, strategic play in the increasingly competitive market for orphan drugs.

Rare diseases, despite their low individual prevalence, represent a critical frontier for medical innovation and a compelling investment thesis. The high unmet need, coupled with a lack of competition and the potential for favorable regulatory pathways, creates a powerful incentive structure. The caliber of this investor syndicate validates both the science behind engasertib and the market opportunity in HHT. These are not generalist funds; they are specialists who understand the long, complex path from lab to market. TCGX, for instance, focuses on catalyst-driven biotechs with strong clinical data, while EQT Life Sciences and Droia bring deep, specialized expertise in rare and genetic diseases. Their participation signals a strong consensus on the quality of Vaderis's program.

"Vaderis has generated compelling clinical evidence supporting targeted AKT inhibition as a novel treatment approach for HHT," said Colin Walsh, Managing Director at Goldman Sachs Alternatives. He noted that the company's "strong scientific foundation, disciplined execution and clear focus on addressing a significant unmet medical need" were key drivers of their conviction. This sentiment was echoed by TCGX Managing Partner Giuliano Marostica, who expressed pleasure in partnering with a "high-quality investor syndicate to advance engasertib through this important stage of development."

A Lifeline for a Long-Ignored Community

Beyond the boardroom, the real significance of today's news lies with the thousands of individuals living with HHT. Affecting approximately 1 in 3,800 people, HHT is a genetic disorder characterized by malformed blood vessels. This leads to a cascade of debilitating and sometimes life-threatening symptoms, including severe, recurrent nosebleeds (epistaxis) that can cause chronic anemia, and the formation of larger arteriovenous malformations (AVMs) in critical organs like the lungs, liver, and brain. For decades, the HHT community has had no approved therapies, relying instead on supportive care, frequent blood transfusions, and invasive procedures to manage a relentless condition.

"Today represents a defining moment for HHT patients," stated Azmi Nabulsi, President and CEO of Vaderis Therapeutics. The initiation of the HEROIC study, he noted, "marks an exciting new chapter" made possible by the dedication of patients, investigators, and advocacy groups. This sentiment underscores the profound human element driving the science. The study's Principal Investigator, Dr. Hanny Al-Samkari of Harvard Medical School, reinforced the urgency. "HHT remains a serious, lifelong disease that places a substantial burden on patients, yet there are still no approved therapies," he said, expressing confidence that the study is well-designed to confirm earlier, encouraging findings.

Targeting the Disease at its Source

The scientific promise of engasertib lies in its precision. This is not a drug that merely manages symptoms; it is an oral allosteric inhibitor of AKT1/2, designed to target the underlying pathophysiology of HHT. In patients with the disease, a key cellular signaling pathway goes into overdrive, promoting abnormal blood vessel growth. Engasertib is engineered to selectively dial down that specific pathway, addressing the root cause of the vascular malformations. This approach holds the potential to be a truly disease-modifying therapy.

This scientific rationale is not just theoretical. The decision to advance to a pivotal Phase 3 trial was built upon a bedrock of strong prior evidence, most notably data published in the prestigious New England Journal of Medicine. Publication in such a top-tier, peer-reviewed journal provides a powerful, independent validation of the drug's potential, demonstrating that engasertib produced clinically meaningful and sustained improvements in earlier studies. Giovanni Mariggi of Medicxi, a co-founder of Vaderis, highlighted this journey: "The advancement of engasertib into Phase 3 represents the culmination of years of disciplined execution, scientific innovation and close collaboration with the HHT community."

The 'HEROIC' Path to Market

The newly initiated Phase 3 HEROIC study is the final gauntlet engasertib must run. As a global, randomized, double-blind, placebo-controlled trial, it represents the gold standard of clinical research. This rigorous design is necessary to definitively prove that the drug is both safe and effective in a larger, more diverse patient population, providing regulators with the high-quality evidence needed for approval. The study will enroll patients with moderate-to-severe HHT across sites in North America, South America, and Europe.

Crucially, the $152 million financing is explicitly intended to see this process through. The company has secured the capital needed to fund its operations not just through the trial's completion, but through regulatory submissions and a potential U.S. approval. This provides Vaderis with a stable runway, insulating its critical development work from market volatility and allowing the team to focus entirely on execution. It marks the company’s full transition from a promising early-stage biotech to a mature, pivotal-stage organization on a clear path to commercialization. Vaderis Therapeutics now stands at a unique intersection of validated science, substantial financial backing, and profound unmet medical need, poised to write the next chapter for an entire patient community.